Apoptosis is a genetically programmed, physiological method of cell destruction. A variety of genes are now recognised as positive or negative regulators of this process. Expression of inducible heat shock proteins (hsp) is known to correlate with increased resistance to apoptosis induced by a range of diverse cytotoxic agents and has been implicated in chemotherapeutic resistance of tumours and carcinogenesis. Intensive research on apoptosis over the past number of years has provided significant insights into the mechanisms and molecular events that occur during this process. The modulatory effects of hsps on apoptosis are well documented, however, the mechanisms of hsp-mediated protection against apoptosis remain to be fully defined, although several hypotheses have been proposed. Elucidation of these mechanisms should reveal novel targets for manipulating the sensitivity of leukaemic cells to therapy. This review aims to explain the currently understood process of apoptosis and the effects of hsps on this process. Several proposed mechanisms for hsp protection against apoptosis and the therapeutic implications of hsps in leukaemia are also discussed. Leukemia (2000) 14, 1161-1173.
Introduction
Normal development of cells and maintenance of tissue homeostasis require tight regulation of proliferation, differentiation and death processes. Deregulation of any of these processes can have severe consequences, resulting in diseases such as leukaemia, autoimmunity, viral infections, allergic and neurodegenerative disorders. [1] [2] [3] Abnormal heat shock protein (hsp) expression has recently been identified as one of the deregulating factors in cellular development and this area is rapidly emerging as an exciting field of research.
Eukaryotic cell death can follow two fundamentally distinct pathways, necrosis or apoptosis. Necrosis is the result of acute cellular dysfunction due to extreme trauma or injury to the cell. It is a passive and disruptive process in which the cell rapidly loses control of ion flux. This leads to the uptake of water, giving rise to cell and organelle swelling, resulting in cytolysis. The release of cell contents into surrounding tissue perpetuates a local inflammatory response. 4 In contrast, apoptosis is a genetically regulated process which, unlike necrosis, occurs through the activation of a cell-intrinsic death cascade. This cascade can be modulated by many exogenous signals. The dying cell undergoes a relatively ordered form of cell death characterised morphologically by cell shrinkage, membrane blebbing, chromatin condensation, internucleosomal DNA fragmentation and the formation of apoptotic bodies. 1, [5] [6] [7] Injured/stressed cells may undergo necrosis or apoptosis, depending on the level of the stress. Under extreme conCorrespondence: TG Cotter; Fax: 353-21-904259 Received 21 January 2000; accepted 27 March 2000 ditions, when the stress level eliminates the capacity for regulated activation of the apoptotic cascade, the cells undergo necrosis. At lower levels, injured cells activate their own apoptotic programme. However, if the level of stress is low enough, cells attempt to survive and activate a stress response system ( Figure 1 ). This response involves a shut-down of all cellular protein synthesis apart from a rapid induction of heat shock proteins, which results in a transient state of thermotolerance. 8 Once the stress element is removed, these cells function normally and the levels of hsps drop back to basal levels with time. During the intervening period, while hsp levels are elevated, cells are refractory to the toxicity of various agents. 9 Many tumour cells, however, appear to have constitutively elevated levels of hsps which may serve to protect them from otherwise harmful conditions/agents. This abnormal hsp expression has recently been implicated in chemotherapeutic resistance and carcinogenesis; [10] [11] [12] and increased activity of hsps appears to result in aggressively growing and therapy resistant tumours. [13] [14] [15] This is a simplified view of the stress response and the cellular protective effects of hsps. In reality, diverse apoptotic signalling pathways are triggered within the cell by different treatment modalities, and these pathways converge at a common point in the apoptotic pathway. Each member of the hsp family appears to have a distinct set of functions within the cell. 9 The mechanisms by which various hsps protect against different apoptotic stimuli remain to be fully defined. In fact, evidence now exists to suggest that certain hsps can enhance apoptosis in some systems. [16] [17] [18] A better understanding of the molecular mechanisms of hsp protection against apoptosis is
Figure 1
The stress response; mild stress triggers the rapid induction of hsps, resulting in thermotolerance. Increasing levels of stress result in the apoptotic response and under extreme conditions necrosis occurs. required before directed therapeutical interventions can be made. This review summarises the regulation of heat shock proteins and the apoptotic process as currently understood. Effects of hsps on the apoptotic process and several proposed mechanisms of hsp protection against apoptosis are also discussed.
Heat shock proteins
The response of cells or organisms to environmental stresses such as heat shock or chemicals is related to the induction or enhancement of a number of heat shock proteins (hsps). Hsps gained their name following experiments by Ritossa in 1962, who exposed Drosphilia salivary glands to heat, dinitrophenol or salycilate. 19 Ritossa observed a new chromosomal puffing pattern following these stresses. Further work by Tissieres in 1974 on protein synthesis following heat shock on Drosphilia salivary gland revealed that heat shock activated the synthesis of only a few polypeptides and strongly inhibited the synthesis of most others. 20 It is now clear that the hsps comprise a large superfamily of proteins that are found in all plant, yeast, bacterial and mammalian cells. 21 Most of the members of the hsp family are universally conserved proteins represented by a spectrum of functional homologues in all cellular compartments and organelles. Hsps are not only induced during stress, some family members are constitutively expressed, indicating a cellular function under normal conditions. This superfamily of proteins are also referred to as 'molecular chaperones', due to their ability to stabilise proteins and polypeptides, thereby minimising protein misfolding and aggregation within the cell. The major families of hsps, and their respective functions, are summarised in Table 1 .
The hsp70 family of proteins function mainly as chaperones, interacting transiently with many proteins in an ATPdependent manner (reviewed in Ref. 22) . Constitutively synthesised members are localised in distinct intracellular compartments including: the constitutive hsp73/hsc70 (cognate) present within the cytosol/nucleus; the constitutive glucose regulated 78 kDa (Grp78 or BiP) protein present within the lumen of the endoplasmic reticulum and the glucose regulated 75 kDa (Grp 75 or mtHsp70) protein present within the mitochondrial matrix. These proteins are also moderately stress inducible under certain conditions. The most strictly Table 1 Heat shock protein families, their expression and functions
Heat shock family Protein expression Main functions 100 Constitutive and stress inducible Thermotolerance in yeast 29 
90

Constitutive
Regulation of cytoskeleton dynamics, cell shape and mobility 9, 30 Prevents aggregation of denatured proteins 31 Regulatory function by interacting with several protein kinases 32 
70
Constitutive and stress inducible Folding of newly synthesised proteins 33 Protein transport and sorting between compartments 32 Regulation of stress response 13 Thermotolerance and resistance to apoptosis-inducing agents 34, 35 60 Constitutive and stresss inducible Mitochondrial chaperone involved in protein import and folding 36 Role in apoptosis regulation 37, 38 small (10-28 kDa) hsps Constitutive and stress inducible Signal transduction to actin microfilaments 39 Thermotolerance and resistance to apoptosis-inducing agents (hsp27) 23, 24 Ubiquitin Constitutive and stress inducible Ubiquitination of proteins for degradation 40 stress inducible member, hsp70 (hsp72) is present at basal levels in unstressed cells, but following stress becomes strongly induced and is present in the cytosol and nucleus. 8 As hsp70 is the major anti-apoptotic hsp, most of the studies investigating mechanisms of hsp protection are carried out using hsp70 overexpression. The apoptotic events that have been proposed to be involved in hsp protection against apoptosis and the theories on mechanisms for this protection are detailed later in the text.
The stress inducible expression of hsp27, a member of the small hsp family, also has a significant role in protection against apoptosis. 23, 24 The intracellular localisation, level of oligomerisation and phosphorylation status of hsp27 appear to be involved in the regulation of its biological reactivity. 25 For example, monomeric, non-phosphorylated hsp27 has been shown to be the only form that inhibits in vitro actin polymerisation, a potential biochemical function of hsp27. 26 However, the active form of hsp27 for other described functions, such as cell protection, has not yet been conclusively determined.
Hsps as molecular chaperones
Molecular chaperones are currently defined as proteins that bind to and stabilise an otherwise unstable conformer of another protein, and by controlled binding and release of the substrate protein, facilitates its correct fate in vivo: be it folding, oligomeric assembly, transport to a particular subcellular compartment or controlled switching between active/inactive conformations. The major classes of hsps that have chaperone functions are hsp70, hsp60 and hsp90 (reviewed in Ref. 27 ).
Hsp70 and hsp60 are not substrate specific, ie they bind to a wide range of unfolded proteins with approximately the same affinity. Both hsp70 and hsp60 chaperones function in conjunction with other proteins, termed co-chaperones, which are specific for their chaperone but can distinguish between ATP-bound and ADP-bound structural variants. Both classes of chaperones are ATPases and ATP hydrolysis provides energy for their function.
An obvious mechanism for hsp protection against apoptosis would, therefore, be the use of their chaperone function. Induction of hsps following stress serves to protect against subsequent stress, presumably by preventing/repairing stressinduced protein denaturation and promoting protein folding.
However, how can this account for hsp protection against stresses like doxorubicin, etoposide, TNF and UV, that do not cause direct protein damage? Furthermore, destruction of the chaperone activity of hsp70 by deletion of the ATP-binding domain results in a protein still capable of providing heat resistance. 28 This suggests that the hsps play a distinct role in thermoprotection.
Induction of the heat shock response
The heat shock response is one of the most potent inducers of gene expression known. At normal temperatures (37°C), the inducible form of hsp70 is virtually undetectable in the cell, however, within minutes of a temperature shift to 42°C, hsp70 becomes the major product of protein synthesis, and within 2 h it accumulates to become one of the most abundant proteins in the cell. 41, 42 This remarkable gene induction is achieved at several different levels. 43 The primary mechanism is the activation of heat shock factors (HSFs) which bind to heat shock elements (HSEs) present upstream of all heat shock genes, to initiate transcription. 44 All conditions or agents capable of inducing hsps do so by activating HSFs. 45 Understanding the mechanisms underlying induction of the heat shock response may provide important information for the control of HSF and hsp expression levels. Activation of HSF and its interaction with DNA are described below.
HSF activation
Members of the HSF family are conserved proteins with distinct domain organisation. Two HSFs exist in humans, HSF1 and HSF2. HSF1 is activated by heat shock and other stresses. HSF2 is thought to be activated during embryonic development and cell differentiation. 46, 47 In unstressed cells, HSF1 is present as a non-active form which has DNA-binding activity. Stress-induced activation of HSF1 involves phosphorylation, oligomerisation and redistribution within the nucleus. It has been demonstrated that hsp90 binds and prevents the activation of HSF1. 48 Following stress treatment, denatured proteins are thought to bind hsp90, causing dissociation of HSF1 and hsp90. This can lead to the phosphorylation of HSFs, leading to HSF activation. The active HSFs form trimers that bind to the promoter of the hsp70 gene to stimulate transcription 47 ( Figure 2 ). HSF1 may be an important potential target for the inhibition of hsp70 expression, as some cytotoxic agents have already been demonstrated to inhibit hsp70 expression by altering HSF1 phosphorylation levels in leukaemic cells. 49 Reactive oxygen species (ROS) have also been proposed to be involved in the activation of HSF, as exposure to many oxidising agents coincides with the accumulation of hsps. 50 ROS have been shown to directly activate HSF1 during ischemia-reperfusion injury 51 and to induce hsp expression in cells. 52 In addition, a study by Gorman et al 53 demonstrates that treatment with antioxidants prior to heat shock results in attenuated hsp expression, suggesting that ROS may be necessary for HSF activation/hsp induction.
In contrast to HSF1, the oligomeric state, properties and localisation of HSF2 are not changed in cells under stressful conditions, and during heat shock this transcription factor remains in a nonactive form corresponding to a homo-or heterodimer. However, in vivo HSF2 is known to be active as a trimer during embryonic development, spermatogenesis and
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Figure 2
Differential regulation of HSF1 and HSF2 DNA-binding activity in eukaryotic cells. HSF1 is present in a non-active form which has DNA-binding activity and is activated by heat shock and other stresses. HSF2 remains in an inactive homo-or heterodimer form during stressful conditions. It is known to be active during differentiation and embryo development. Once activated, HSFs are phosphorylated and oligomerise into trimers that bind to the HSE in the promoter region of the hsp70 gene.
hemin treatment. 47 It has been recently demonstrated that HSF2 has a role in the differentiation of multipotential hematopoetic cells into erythroid lineage precursors. Enhanced HSF2 expression and the acquisition of HSF2 DNA binding activity are strictly specific for erythroid characteristics of K562 cells. This report suggests that HSF2 could function as a lineage-restricted transcription factor during differentiation of K562 erythroleukemia cells. 54 We may, therefore, consider HSF1 and HSF2 as two different regulatory effectors of hsp synthesis. HSF1 is responsible for rapidly triggering the transcriptional response to increase hsp levels in cells undergoing environmental or pathophysiological stresses; HSF2 is a developmental activator of nonstress-induced heat shock gene transcription. 46, 47 Heat shock gene transcription Activated HSFs associate with specific target DNA sequences within the promoter region of heat inducible genes. These target sequences, commonly termed heat shock elements (HSE) are highly conserved from yeast to humans. Transcription elements for the TATA-binding protein (TBP) and GAGA factor are also present on the promoter. 44 In addition, uninduced heat shock gene promoters are usually preassembled into an open configuration at normal temperatures. 43 RNA polymerase II is associated with these genes and appears transcriptionally engaged but arrested in elongation. 44, 55 The binding of TBP to the TATA sequence is necessary to regulate the activity of RNA polymerase II. The presence of paused RNA polymerase II in the promoter region of uninduced heat shock genes serves as a preactivation of these genes to provide their maximally rapid expression once HSF binds. The absence of intervening sequences in the hsp70 gene, a unique attribute of the heat-inducible members of the gene family, allows hsp70 transcripts to circumvent the block in intron processing that occurs at elevated temperatures.
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Regulation of the heat shock response by hsps
Many observations indicate that the elevation of intracellular hsp levels is accompanied by the termination of hsp transcription and deactivation of HSF; thus, it is speculated that hsps themselves negatively regulate heat shock gene transcription via an autoregulatory loop. 57, 58 Experiments demonstrate that activation of HSF in response to temperature elevation was markedly reduced in cells containing a large amount of hsp70 which had experienced previous heat shock, 59 in cells overexpressing hsp70, 60 or in cells microinjected with exogenous hsp70. 61 Hsp90 is also involved in the mechanism of negative regulation, since it binds to the nonactive form of HSF, however, it cannot bind active HSF. 59 This theory is further supported by the compound geldanamycin, a selective hsp90-binding agent. Geldanamycin has the ability to disrupt the interaction between hsp90 and target proteins, and has been demonstrated to induce HSF1 phosphorylation, HSE binding activity, hsp70 and hsp27 expression. 62 This indicates that functional inactivation of hsp90 by geldanamycin potentially stimulates the expression of hsps through the activation of HSF1.
Apoptotic signalling -regulation by hsps?
Different treatment modalities and environmental factors initiate the apoptotic response in various ways, including death receptor activation or oxidative stress induction. These mechanisms, and their regulation by hsps, are discussed in detail below.
Fas receptor-mediated apoptosis
Death receptors, such as Fas (APO-1/CD95), are cell surface receptors that transmit apoptosis signals initiated by specific death ligands and play a central role in instructive apoptosis. The Fas antigen is a 48 kDa cell surface protein that belongs to the tumour necrosis factor (TNF) superfamily of surface receptors. 63 Members of this family are characterised by the presence of a death domain (DD) within their cytoplasmic region and have been shown to trigger apoptosis upon binding of their cognate ligands or specific agonistic antibodies. Stimulation of Fas results in the aggregation of its intracellular DDs, leading to the recruitment of two key signalling proteins (FADD/MORT-1 and caspase-8/FLICE/Mch5) that, together with the receptor, form the death-inducing signalling complex (DISC). 64 Downstream of DISC, the Fas signalling pathway has been shown to involve the activation of a caspase cascade (detailed in caspase section). 65 Fas has an important role in lymphocyte homeostasis and is widely expressed on normal and malignant hematopoietic cells, and on cells outside the immune system. The significance of Fas expression by leukaemic cells with regard to its prognostic and therapeutic implications has been an active, and somewhat controversial, area of research. Conflicting research exists in the area of Fas as a target for therapy. The inhibition of proliferation and induction of apoptosis in several human lymphoid lines and primary leukaemic cells by nanogram amounts of anti-Fas antibody has been demonstrated by some laboratories, [66] [67] [68] however a different anti-Fas antibody has been found to cause hepatotoxicity by another group. 69 Similar contrasting evidence exists in the involvement of Fas expression in drug-induced apoptosis and in the role of Bcl-2 in Fas resistance (reviewed in Ref. 70 ). These contrasting observations suggest that the role of Fas expression in leukaemic and other cells may be dependent on the cellular status of other pro-and anti-apoptotic proteins, and that a heterogeneity in the regulation of this pathway may exist.
Hsp27 appears to inhibit apoptosis mediated through Fas and other receptor-mediated pathways. This small hsp has been demonstrated to block apoptosis induced by Fas, staurosporine (a protein kinase C inhibitor), monocytes, hydrogen peroxide and anti-cancer drugs. 14, 15, 35, 71, 72 Hsp27 fails to inhibit apoptosis induced by p53, UV radiation and lymphokine-activated killer (LAK) cells. [72] [73] [74] Constitutive expression of hsp27 has been identified as being a marker for common acute lymphoblastic leukaemia (ALL) 75 and has been implicated in drug resistance to AML cells. 11 Hsp27 is thought to regulate apoptosis by maintaining the redox equilibrium of the cell 76 and has been demonstrated to inhibit apoptosis by increasing the intracellular level of the antioxidant glutathione (GSH). 77 Fas-induced apoptosis, which is not inhibited by hsp70 and does not produce ROS during its apoptotic induction, has been reported to extrude GSH from the cell as part of its apoptotic mechanism. 78 Although ROS do not act as mediators in the execution phase of Fas-mediated apoptosis, they have been implicated in the transcriptional regulation of Fas ligand expression. 79 The increased GSH levels during hsp27 expression could, therefore, account for its role in protection against Fas-mediated apoptosis.
Interestingly, it has been reported that hsp70 synthesis, while inducing thermotolerance, can render leukaemic T cells more susceptible to receptor-mediated Fas and TCR/CD3-induced apoptosis. 17 Further studies have reported enhanced apoptosis when hsp70 levels are increased in various cells, including human leukaemic T cells, lymphoid cells, ovarian luteal cells and CD4 + lymphocytes. [80] [81] [82] [83] Hsp90 has also been implicated in the induction of apoptosis; Galea-Lauri et al 16 demonstrated hsp90 overexpressing transformed haemopoietic cells to have increased apoptosis in response to TNF in combination with cyclohexamide. Conversely, antisense transfected cells that expressed less hsp90 were relatively protected from apoptosis. The requirement for cycloheximide with TNF␣ suggests that elevated hsp90 associated with apoptosis may be linked to the chaperone function of the protein and the effect could be due to the blockade of an apoptotic inhibitor, the identity of which is unknown.
Oxidative stress-mediated apoptosis
Intracellular oxidative stress may be generated via increased production of reactive oxygen species (ROS) and/or the depletion of intracellular antioxidants, such as glutathione (GSH) and antioxidant enzymes catalase and superoxide dismutase (SOD). The term ROS is a collective one that includes free radicals such as the superoxide anion, hydroxyl radical and some non-radical derivatives of oxygen, such as hydrogen peroxide (H 2 O 2 ).
Oxidative stress, once generated within cells, may trigger the apoptotic cascade via many mechanisms (reviewed in Ref. 84). Environmental oxidants that induce excess ROS production during their cytotoxic mechanism include ultraviolet and ionising radiation, heavy metals, redox active chemicals, anoxia and hyperoxia. [85] [86] [87] [88] Exogenous oxidants, such as H 2 O 2 , nitric oxide (NO) and oxidised low density lipoproteins have been demonstrated to induce apoptosis in a range of cell types. [89] [90] [91] In addition to the cytotoxic effects of exogenous free radicals, several agents (including many chemotherapeutic drugs) which are not themselves considered oxidants, generate ROS during the induction of apoptosis. 92, 93 Furthermore, the induction of apoptosis by transcription factor p53 has recently been demonstrated to be dependent on ROS production. 94 The role for oxidative stress in the induction of apoptosis is further supported by the ability of a broad range of antioxidants to inhibit apoptosis induced by non-oxidant stimuli, such as cytotoxic drugs. 92 The depletion of an important cellular antioxidant, such as GSH, would lower the reducing potential of the cell, causing oxidative stress without an increase in ROS levels. Glucocorticoid-induced thymocyte apoptosis has also been shown to result in GSH depletion. 95 In addition, the GSH depleting agent buthionine sulfoximine (BSO) has been found to cause toxicity in leukaemic cells at clinically achievable concentrations. 96 Acute myeloid leukaemia (AML) blast populations and human T cell leukaemia virus type 1 (HTLV-1) infected lymphocytes have been shown to be particularly susceptible to BSO toxicity, which manifested as the appearance of high ROS levels. 96, 97 Hsp70 appears to increase resistance against oxidative stress-mediated apoptosis. Reports demonstrate hsp70 inhibiting apoptosis induced by ethanol, hydrogen peroxide, TNF, UV radiation and several chemotherapeutic agents.
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Many, if not all, of these treatments have been found to produce ROS within cells during their apoptotic induction.
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Hsp70 appears to be preferentially expressed in high-grade malignant tumours compared to low-grade tumours and surrounding tissues. [102] [103] [104] Hsp70 is associated with chemotherapeutic resistance in many forms of leukaemia. 105, 106 Conversely, the susceptibility of AML cells to apoptosis has been shown to correlate with hsp70 expression. 80 A recent publication from our laboratory reports the selective protection by hsp70 against agents which induce ROS production during their apoptotic mechanism. 42 Cytotoxic agents such as actinomycin-D and camptothecin were shown to produce ROS in treated leukaemic cells. Treatment with antioxidants inhibited apoptosis to the same extent as hsp70 overexpression. However, hsp70 had no inhibitory effect on the induction of apoptosis by anti-Fas treatment. This observation suggests that the inhibitory function of hsp70 is only effective against agents which produce ROS during their apoptotic induction. Receptors, such as Fas and TCR mediate apoptosis independent of ROS production 107, 108 and have even been demonstrated to have enhanced apoptosis when hsp70 is overexpressed. 17 Further support for this observation comes from the fact that TNF, a Fas-related death receptor, relies on a ROS burst to trigger the apoptotic cascade 109 and thus, protection against TNF-induced apoptosis has been mediated by hsp70. 99 Oxidative stress has been proposed as a central common mediator of apoptosis, 110 which is not surprising when the extent of stimuli that have been shown to cause oxidative stress during their apoptotic induction is considered. It is thought that mitochondria may be the primary target of oxidative stress; 111 the effects of mitochondrial damage are discussed in detail later.
The mechanisms by which the hsps regulate apoptosis are still undefined, however, this appears to be an emerging area of exciting research. Hsps may have an important role in the regulation of apoptosis, as hsps such as hsp27 and hsp70 have an inhibitory effect on apoptosis (summarised in +, protective effect; −, no effect; +/−, protective effect in some cells, not in others; ND, not determined.
apoptotic pathways. 16, 17 It is unclear why hsp70 and hsp90 inhibit apoptosis in some conditions and not others. It is conceivable, however, that hsp70 may be acting on an early signalling event which could have a pro-apoptotic effect on some apoptotic pathways (eg Fas and TCR/CD3) and an antiapoptotic effect on others (eg oxidative stress-mediated apoptosis). The mechanisms by which hsps upregulate the apoptotic process are poorly investigated to date. However, several mechanisms of hsp protection have been proposed. Conceivably, hsps might either limit cell damage and thereby blunt the death signal or prevent the activation or activity of sensor or effector molecules. The anti-apoptotic hsps, hsp27 and hsp70, appear to inhibit apoptosis by different mechanisms, as they have a different specificity for the apoptotic inducers against which they confer protection.
The influence of hsps on signal transduction pathways
A number of groups have recently demonstrated that activation of the stress-activated protein kinase (SAPK) signal transduction pathway, which leads to activation of JNK, can be inhibited by hsp70. 13, 112 Heat shock-induced hsp70 gene expression inhibited JNK activity in response to toxic compounds like ceramides and harsh conditions such as UV exposure. 13, 112, 113 Hsp70-mediated inhibition appears to be occurring upstream of JNK1 activation and PARP cleavage. However, cells that were transfected with hsp70 and were constitutively overexpressing the protein had no inhibitory effect on JNK activation, 13, 112, 114 even though they were equally potent in conferring resistance to apoptosis. This suggests that, although inducible hsp70 can block JNK activation, this inhibition is unrelated to its protective mechanism. In support of this hypothesis, Lee and Corry 115 used cells transfected with a dominant negative JNK1 to demonstrate that the SAPK pathway is involved in activation of HSF and hsp70 gene expression. Their data suggest that hsp70 gene expression is a consequence of the SAPK pathway, therefore once hsp70 was expressed it would inhibit this pathway via negative feedback regulation. This would explain why constitutively overexpressed hsp70 has no effect on JNK activation.
Another stress-activated kinase, p38 mitogen-activated kinase (MAPK) has been implicated in the regulation of apoptosis. It has been shown that overexpression of kinases that activate p38MAPK result in the induction of apoptosis. 116 Additionally, inhibition of p38MAPK activity has been shown to suppress apoptosis. 117 Purified recombinant hsp70 has been demonstrated to inhibit the activation of p38MAPK activity by 40-70%, 112 however, as with JNK1 activity, only cells with induced hsp70 could inhibit p38MAPK activity. This suggests that p38MAPK, like JNK1, is involved in the induction of hsp70 rather than its mechanism of protection.
A further mechanism for the anti-apoptotic effect of hsp70 may involve its interaction and subsequent inhibition of some of the genes that drive apoptosis. Hsp70 can interact with both p53 and c-Myc. 118, 119 Hsp70 binding to the mutant p53 protein may stabilise the protein in its mutant conformation, preventing the pro-apoptotic function of wild-type p53, thus contributing to tumorigenesis. Co-localisation studies have revealed hsp70 and c-Myc co-localisation in phase-dense nuclear structures, 119 thus hsp70 may act to modulate functional levels of c-Myc protein. Hsp70 has previously been shown to reduce free levels of c-Myc in cells. 120 Constitutively, hsp90 is an obligate component of fundamental cellular processes, such as hormone signalling and cell cycle control, and several signal transduction systems utilise an interaction with hsp90 as an essential component of the signalling pathway (reviewed in Refs 121, 122) . The importance of hsp90 in signalling pathways has been highlighted with the use of the drug, geldanamycin, which selectively binds hsp90. 123 Targeting of hsp90 by geldanamycin has been shown to cause destabilisation of mutant p53 124 and disruption of MAPK signalling via destabilisation of Raf-1. 125 These effects of geldanamycin and its analogues correlate with antitumour effects of this class of agents 126 and clinical studies of this drug are currently in progress.
Modulators of apoptosis and the heat shock response
Caspase activation in apoptosis
The caspases are a family of cysteine proteases that have become recognised as key components of the apoptotic machinery. 127 This family of cysteine-dependent enzymes cleaves its target substrates on the C-terminal side of aspartate residues. Many biochemical and morphological events of apoptosis are a direct result of caspase-mediated cleavage substrates. The importance of caspases during leukaemia cell apoptosis is confirmed by some recent publications. Firstly, the synthetic retinoid, CD437 has been shown to induce rapid apoptosis of both retinoic acid-sensitive and resistant AML cells. The rapid induction of apoptosis was demonstrated to be directly due to caspase-3 proteolysis. 128 In addition, the human leukaemic cell line, TUR, is resistant to chemotherapeutic drug-induced apoptosis. This resistance has recently been demonstrated to be due to a signalling defect in the activation of caspase-3 and PKC delta. 129 Caspase substrates include proteins involved in DNA replication and repair, 130, 131 structural components of the cell, such as actin and nuclear lamins, whose cleavage probably facilitates chromatin condensation and cellular disassembly 132 and proteins that mediate cell survival pathways, such as PKB/Akt, Raf-1 and Bcl-2 family members. 133, 134 Caspases exist in the cell as inactive zymogens (procaspases). Conversion to the active caspase form involves procaspase proteolysis to produce two subunits that constitute the active enzyme (reviewed in Ref 135) . On the basis of their primary structures, caspases can be grouped into two classes: those that possess long N-terminal domains (class I caspases) and those that possess short prodomains or lack prodomains (class II caspases). The prodomains in class I caspases (eg caspases-2, -8, -9 and -10) contain protein binding domains that recruit class I caspases to death complexes. Activation of class II caspases (eg Caspases-3, -6, and -7) appears to require proteolytic processing by active class I caspases. 136 Class I caspase activation is important for cell death commitment and class II caspases are, therefore, the downstream caspases that mediate proteolysis of cellular substrates.
The first evidence for direct recruitment of a class I caspase to a death complex was the observation that caspase-8 associates with the Fas death-inducing signalling complex by binding the adapter molecule FADD. 137, 138 Once active, caspase-8 is liberated into the cytosol where it can initiate a cascade of class II activation. 139 An alternative pathway involving the mitochondria in Fas signalling has also been demonstrated. 140 This pathway can be blocked by the anti-apoptotic oncogene, Bcl-2, whereas DISC-mediated apoptosis cannot (Figure 3) .
Procaspase-9 can be activated following the formation of an 'apoptosome' complex with Apaf-1 (apoptosis activating factor-1) 141 and cytosolic cytochrome-c, 142 in a dATP-dependent manner. 143 It appears that dATP and cytochrome-c binding induce a conformational change in Apaf-1, exposing its CARD (caspase recruitment domain). The formation of multimeric Apaf-1/cytochrome-c complexes appears to induce procaspase-9 activation through oligomerisation 144 ( Figure 3 ). Hsp27 has recently been demonstrated to inhibit etoposideinduced apoptosis by preventing cytochrome-c and dATP-triggered activity of caspase-9, downstream of cytochrome-c release. 145 The regulation of non-receptor-mediated caspase activation by mitochondria is further supported by studies demonstrating caspase-3 localisation to this organelle. 146, 147 The mitochondrial pool of caspase-3 is normally latent, but is redistributed to the cytoplasm following activation. 147 Caspase-6 has recently been identified as being the protease responsible for
Figure 3
Receptor-and stress-mediated mechanisms of apoptotic induction. Activation of Fas by its ligand results in the aggregation of its death domains (DD) and recruitment of FADD. The death effector domain (DED) of FADD recruits procaspase-8. This complex may result in the direct activation of the caspase cascade or indirect caspase activation via a mitochondrial pathway. Oxidative stress inducing agents cause mitochondrial alterations including the release of cytochrome-c (cyt-c), which binds APAF-1 in a dATP-dependent manner. APAF-1 then recruits procaspase-9 via its caspase recruitment domain (CARD), resulting in the activation of a caspase cascade. the proteolytic activation of caspase-3 during camptothecininduced apoptosis in Jurkat cells. 38 Interestingly, this group revealed that caspases-3 and -6 exist as part of a multiprotein complex which also contains the mitochondrial chaperonin hsp60. Furthermore, activation of procaspase-3 by upstream proteases was shown to be promoted by hsp60. In support of these findings, Samali et al 37 report the association of mitochondrial procaspase-3 with hsp60 and hsp10. Following induction of apoptosis, procaspase-3 was activated and dissociated from the hsp complex. This occurred simultaneously with release of hsp60 and hsp10 from mitochondria. This group also reveal that recombinant hsp60 and hsp10 accelerate procaspase activation in vitro, suggesting that these hsps may serve as positive regulators of caspases during apoptosis.
The ability of caspase inhibitors to prevent apoptosis in many model systems led to the suggestion that this group of proteases participates in cellular life/death decisions. However, evidence is now emerging for a caspase-independent form of cell death. Recent reports demonstrate that, in the absence of caspase activity, other apoptotic events, such as phosphatidylserine (PS) externalisation to the cell surface, mitochondrial alterations, membrane blebbing, cell shrinkage and nuclear condensation/fragmentation can still occur. [148] [149] [150] [151] [152] [153] The activity of the caspases can be inhibited by the synthetic peptide Ac-DEVD-CHO, which mimics the recognition site in PARP, a caspase-3 substrate. 154 Interestingly, the hsp70 molecule has a conserved C-terminal sequence -EEVD. Removal or mutation of this sequence results in a loss of substrate binding ability. 155 This sequence may, therefore, be involved in the mechanism which results in the ability of hsp70 to exert its anti-apoptotic function downstream of caspase-3-like proteases. 114 In this study, hsp70 inhibits the apoptotic cascade downstream of cytochrome-c release and caspase-3 activation. Hsp70 did, however, confer significant protection from cell death induced by enforced expression of caspase-3, suggesting that the consequences of caspasemediated proteolysis are inhibited by hsp70. Mosser et al 13 investigated whether this C-terminal EEVD sequence was capable of inhibiting the caspase cascade. This group examined the interaction between hsp70 and the active site of caspase-3. They found that hsp70 did not inhibit the activity of caspase-3 in vitro, even in the presence of ATP or its nonhydrolyzable analogue. In addition, data from our laboratory demonstrate that hsp70 inhibits caspase-dependent and -independent oxidant-induced apoptosis, 192 thus ruling out the involvement of caspases in the protective mechanism of hsp70. However, the possibility still remains that caspases may interact with, or cleave, hsps at their EEVD sequence, thereby negating their cytoprotective properties. This may occur in situations where cytoprotection is overwhelmed. For example, the cytoprotective properties of Bcl-2 and Bcl-XL have been demonstrated to be lost during caspase-mediated cleavage.
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Mitochondrial alterations during apoptosis
Mitochondria are receiving considerable attention in apoptosis research at present. The ability of mitochondria to release the potent proapoptotic factors, cytochrome-c, 142 apoptosis inducing factor (AIF) 157 and procaspases-9, -3 and -2, 147,158 from their intermembrane space has led to the suggestion that mitochondria are central regulators of the death process. 159 Cytochrome-c, an essential component of the electron Leukemia transport chain, is capable of triggering the caspase cascade once exported to the cytoplasm. 160 The caspase cascade is initiated by cytosolic cytochrome-c binding to Apaf-1 and procaspase-9, which results in the activation of caspase-9. 143 The inability of caspase inhibitors to prevent cytochrome-c translocation indicates that this event is upstream of caspase activity. 161 AIF is subject to nuclear translocation upon induction of apoptosis by diverse stimuli. 162 In the nucleus, AIF is thought to contribute to DNA fragmentation, presumably by activating a sessile nuclear DNase. 162 The apoptotic functions of AIF appear to be caspase-independent (reviewed in Ref. 163) .
Alterations in mitochondrial transmembrane potential (⌬⌿m) are thought to occur via the opening of a permeability transition (PT) pore on the mitochondrial outer membrane. 159 It has been suggested that repeated, rapid opening and closing of the PT pore may allow the release of cytochrome-c into the cytosol without the detectable loss of ⌬⌿m. 164 This implies that the subsequent rupture of the outer mitochondrial membrane may serve as an amplification step for the release of caspase activating proteins from the mitochondria. Inhibitors of PT opening, which include Bcl-2 and Bcl-XL, have also been demonstrated to be efficient inhibitors of apoptosis. 165 Depletion of mitochondrial Ca 2+ , 166 Bax and other oxidants that directly affect PT have also been shown to induce membrane disruption and release of caspase activating molecules. 157, 165 The mechanism through which hsp70 mediates ROSinduced death appears to reside at the mitochondrial level. 167 Mitochondria are thought to be the major targets for ROS 111 and Polla et al demonstrated that heat shock protected against H 2 O 2 -induced alterations in mitochondrial membrane potential, mass and ultrastructure. The kinetics of hsp70 accumulation in the cell correlated with the protection against mitochondrial damage. Furthermore, when heat shock was performed in the presence of the translational inhibitor actinomycin-D, hsp70 accumulation, protection against mitochondria and apoptosis were abolished. 167 Alterations in mitochondrial membrane permeability leads to the release of proapoptotic factors cytochrome c and AIF from the mitochondria. 168 Hsp70, therefore, may be inhibiting oxidative stress-mediated apoptosis by blocking their release from the mitochondria. Results from our laboratory have shown that cytochrome-c release is inhibited during hsp70-mediated protection against apoptosis, suggesting that hsp70 is acting at, or upstream of, the mitochondrial level.
The Bcl-2 family
Bcl-2 is by far the most studied anti-apoptotic protein and is now recognised as a general anti-apoptotic protein capable of protecting cells from a wide variety of apoptotic stimuli, including growth factor withdrawal, cytotoxic drugs, irradiation, heat and, only in some cells, from activation of death receptors. [169] [170] [171] [172] [173] [174] [175] [176] [177] The mechanism of action of Bcl-2 is still undefined, however, accumulating data suggest that Bcl-2 may function at several steps of the apoptotic signalling cascade.
At least 16 mammalian Bcl-2-related proteins have been identified to date. They can be classified into anti-apoptotic proteins closely related to Bcl-2 (Bcl-x, Mcl-1, A1 and Boo), and more distantly related pro-apoptotic proteins (Bax, Bak, Bok, Bik, Blk, Hrk, BNIP3, Bim, Bad, Bid and Diva) (reviewed in Refs 178-180) . The clearest correlations between high Bcl-2 expression and poor prognosis are found in non-Hodgkin's lymphomas and AML. 181, 182 In contrast, Bcl-2 expression does not correlate with the response to chemotherapy in patients with chronic lymphocytic leukaemia (CLL). 183 The anti-apoptotic members of the Bcl-2 family of proteins are also suggested to inhibit apoptosis at the level of the mitochondria, possibly by blocking cytochrome c release. 165 It is possible that hsp70 protection may involve direct or indirect association with Bcl-2 family members. The Bcl-2 binding protein, BAG-1, associates with survival proteins such as Raf-1, growth factor receptors and both the constitutive and inducible forms of hsp70. 184 This study demonstrates hsp70/hsc70 chaperone function modulation by BAG-1, that purified BAG-1 binds hsp70 from cell lysates, and that BAG-1 protects some, but not all, cells from heat shock-induced death. 184 This suggests that BAG-1 may be an intermediate protein in the association of hsp70 and Bcl-2, causing inhibition of apoptosis. In support of this theory, increased expression of Bcl-2 has been reported to accompany the induction of hsps by a number of heat shock inducing agents. 167 In addition, BAG-1 levels have been found to be consistently high in leukaemia and lymphoma cell lines in comparison to normal human tissue, which implies a role for BAG-1 in cell survival.
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Multidrug resistance and hsps
Multidrug resistance (MDR) may arise from alterations at any step in the cell killing pathway. Alterations have been described in drug transport, drug metabolism, cellular repair mechanisms and in the ability of the cells to undergo apoptosis (reviewed in Ref. 186) . Hsps have been implicated in multidrug resistance, as they have been repeatedly demonstrated to inhibit apoptosis induced by a range of chemotherapeutic agents. 35, 42 Many of the most important cytotoxic drugs target topoisomerase enzymes. DNA topoisomerase enzymes change the topological state of DNA by breaking and rejoining the phosphodiester backbone of DNA. There are two general classes of topoisomerases. Type I enzymes induce transient singlestranded breaks in DNA and type II enzymes induce transient double-stranded breaks in DNA. Camptothecin and its analogues are the only agents known to specifically inhibit topoisomerase I. The cytotoxic actions of the topoisomerase II targeting drugs, which are more widely used in the treatment of leukaemia, are dependent on their ability to trap the DNA strand passage intermediate, known as the cleavable complex (reviewed in Ref. 187 ). Stabilisation of the cleavable complexes, resulting in expression of DNA strand breaks, are thought to initiate the apoptotic cascade. Examples of topoisomerase II inhibiting drugs are actinomycin-D, etoposide, doxorubicin and mitoxantrone.
Hsp70 has been demonstrated to inhibit apoptosis induced by both topoisomerase I and II targeting agents. 35, 42 Results from our laboratory suggest that the production of ROS by these drugs has a major role in their apoptotic induction, as pre-treatment with antioxidants renders leukaemic cells more resistant to these agents. 42 Furthermore, MDR cells have been shown to have constitutively activated HSF, which would presumably result in increased hsp expression levels. 11 Quercetin, which interferes with the formation of the complex between HSE and HSF, can sensitise MDR cells against chemotherapeutic drugs. Consistent with this observation, quercetin was also shown to decrease the expression level of P-glycoprotein (P-gp) in a dose-dependent manner, suggesting that this inhibitor can decrease expression of P-gp via inhibition of HSF DNA-binding activity. HSF, therefore, may be an important target for chemosensitization of MDR cells.
Many attempts have been made to establish the inhibitory effects of modulating pro-/anti-apoptotic proteins in MDR, such as the hsps, Bcl-2, Fas and p53. However, drug resistance in leukaemia usually appears to be multifactorial. 188 A recent study analysed the expression of P-gp, multidrug resistance protein (MRP), Bcl-2, mutant p53 and hsp27 in remission and blast AML patients, however no significant correlation was observed. 189 This group concluded that drug resistance in AML is multifactorial, and co-expression of at least two of these proteins appears to be a prognostic factor for treatment failure. It is conceivable, therefore, that leukaemic cells may recruit a number of mechanisms, including the activation of HSF and overexpression of hsps, in the pursuit of chemoresistance.
Conclusions
Heat shock proteins are ubiquitous, evolutionary conserved proteins with multiple intracellular functions. Hsps induced by stress treatment have a role in the modulation of apoptosis and have been implicated in the resistance of tumour cells to potential therapeutic agents. Hsp70 and hsp27 have been associated with chemotherapeutic resistance in many forms of leukaemia. 11, 105, 106 In addition, the effectiveness of antisense technology against hsp70 and hsp27 have been clearly demonstrated in vitro. 190, 191 As expected, the resulting reduction in protein expression levels has correlated with an increased susceptibility to drug-induced apoptosis. The mechanism of cellular protection used by hsps has yet to be fully defined, however, a number of plausible theories now exist (summarised in Figure 4) . Therapeutically, inhibition of inducible hsp expression or activity should not cause any
Figure 4
Schematic representation of possible mechanisms by which hsp70 and hsp27 may inhibit apoptosis. Hsp70 inhibits the apoptotic pathways induced by ROS-producing agents such as TNF␣, heat, cytotoxic drugs and radiation. Hsp27 inhibits Fas and other receptor-mediated apoptosis, and activation of caspase-9. Bag-1 may mediate the association of hsp70 to Bcl-2 and inhibit cytochrome-c (cyt-c) release from mitochondria. Hsp70 may also mediate its antiapoptotic effects by binding to mutant p53, causing a decrease in wild-type p53 (w.t. p53) or c-Myc, reducing the cellular levels of free c-Myc. undesired side-effects, because the expression of these proteins is specific to cancer cells. However, in certain cell types and under specific conditions, hsps can actually enhance apoptosis. It is crucial, therefore, that a better understanding of the molecular mechanisms of hsp protection in specific apoptotic pathways is obtained before therapeutic strategies for the regulation of hsp expression/activity are devised.
